ClinicalTrials.gg
Not yet recruitingNCT06088433Updated Oct 18, 2023

Ticagrelor Single Antiplatelet Therapy in Patients With High Risk of Bleeding After DCB for Coronary Small Vessel Disease

A Phase 4 interventional study of Ticagrelor and Clopidogrel in Coronary Heart Disease, sponsored by Fu Wai Hospital, Beijing, China. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-18.

Sponsored by Fu Wai Hospital, Beijing, China · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
292
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing ticagrelor in Coronary Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Ticagrelor · Coronary Disease.

Planned enrollment
5th of 12
292 · median 70
Started
2023
the only one that year
Phase 4
8 of 12
1 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
Fu Wai Hospital, Beijing, China

Among the 12 studies testing ticagrelor in Coronary Disease, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is one of 8 in phase 4, and was the 11th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

2 of the 12 studies testing ticagrelor in Coronary Disease are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing ticagrelor in Coronary Disease, or all of them as a file.
02

Study summary

The present study is aimed to determine the safety and efficacy of Ticagrelor single antiplatelet therapy (SAPT) in patients with primary coronary small vessel disease at high risk of bleeding after drug coated balloon (DCB) therapy.

Read the detailed description

This is a prospective, randomized, open-label, blinded-endpoint evaluation, single-center Study. There will be 234 patients with high-risk bleeding and primary coronary small vessel disease after DCB enrolled in our research, randomly dividing into an experimental group (Ticagrelor SAPT, 90mg BID * 1 month, followed by 60mg BID, n=117) and a control group (DAPT, aspirin 100mg QD+clopidogrel 75mg QD * 1 month, followed by clopidogrel 75mg QD, n=117).The primary endpoint is 12 months of Major adverse cardiovascular events (MACE), including death, myocardial infarction, stroke, and target vessel revascularization. The key secondary endpoint is MACE at 1 month. The safety endpoint is BARC bleeding at all levels. Follow up will be conducted at 1 month and 12 months, and platelet inhibition rate will be measured.

03

Conditions studied

  • Coronary Heart Disease

Browse trials for

Keywords

  • CHD
  • DCB
  • SAPT
  • Ticagrelor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CHD patients aged 18-80 with clear indications for PCI, regardless of gender;
  2. Received DCB treatment with only one small coronary artery (diameter 2.0-2.75mm);
  3. High risk of bleeding (ARC high risk criteria for bleeding): Meets at least one main criterion (use of anticoagulants, liver dysfunction, tumors, history of gastrointestinal bleeding, history of peptic ulcers, rate\<30mL/min, \<11g/L, count\<100 × 109/L) or 2 sub criteria (age ≥ 75 years old, creatinine clearance rate\<60mL/min, history of stroke/, hemoglobin 11-12.9g/L for males or 11-11.9g/L for females);
  4. Willing to participate in trials and complete follow-up;
  5. Signed an form approved by the Ethics Committee;

Exclusion criteria

Exclusion Criteria:

  1. Simultaneously or plan to perform other coronary PCI procedures in batches, including stent implantation, DCB treatment for non-small vessel lesions, and DCB treatment for in stent restenosis lesions.
  2. High ischemic risk: a. ACS within 1 year; b. Perform stent implantation or CABG surgery within 1 year; c. Double or multi vessel lesions rearched incomplete revascularization; d. In addition to the target lesions for DCB intervention, there are other stenosis ≥ 90%, regardless of whether PCI is planned or not;
  3. Anticoagulant drugs are required for atrial fibrillation/deep vein thrombosis (including pulmonary embolism)/mechanical valve implantation;
  4. Cardiomyopathy (HCM/DCM/RCM);
  5. Severe ventricular arrhythmias requires radiofrequency ablation or ICD implantation;
  6. (bronchial asthma, chronic bronchitis, emphysema, pulmonary heart disease);
  7. Serious infectious diseases, including active , or AIDS patients;
  8. Blood system diseases with coagulation disorders such as thrombocytopenia, leukemia, and hemophilia;
  9. Thrombotic diseases such as antiphospholipid antibody syndrome;
  10. Cognitive impairment;
  11. Not willing to participate in experiments or cooperate with follow-up;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
292 participants (estimated)

Study arms

  • Experimental
    SAPT

    Ticagrelor SAPT 90mgBID for 1 month, followed by 60mgBID

    Drug: Ticagrelor

  • Active comparator
    DAPT

    Aspirin 100mgQD+Clopidogrel 75mgQD for 1 month, followed by clopidogrel 75mgQD

    Drug: Clopidogrel · Drug: Aspirin

Interventions

  • Comparison of 12 month of ticagrelor SAPT(90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

    Also known as: Brilinta/Brilique

  • Comparison of 12 month of ticagrelor SAPT(90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

  • Comparison of 12 month of ticagrelor SAPT(90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

    Also known as: Acetylsalicylic Acid

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events

    A composite of mortality, non-fatal myocardial infarction, non-fatal stroke or target vessel revascularization

    Time frame: 12 months after randomization

Secondary outcomes

  1. Major Adverse Cardiovascular Events (Key secondary endpoint)

    A composite of mortality, non-fatal myocardial infarction, non-fatal stroke or target vessel revascularization

    Time frame: 1 month after randomization

  2. Platelet inhibition rate (thromboelastogram)

    Time frame: 12 months after randomization

  3. Rate of patients taking medicine as prescribed

    Time frame: 12 months after randomization

  4. Rate of patients discontinued medication due to bleeding

    Time frame: 12 months after randomization

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Nov 2024, 12 months later.

Of 26 phase 4 interventional studies under Coronary Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 58. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Oct 18, 2023
StartEst.
Nov 15, 2023
Primary completionEst.
Nov 30, 2024
CompletionEst.
Nov 30, 2025
Last update
Oct 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06088433
Lead sponsor
Fu Wai Hospital, Beijing, China
Responsible party
Qian Haiyan (MD, PhD, Fu Wai Hospital, Beijing, China) — Principal investigator
First posted
Oct 18, 2023
Start date
Nov 15, 2023 (estimated)
Primary completion
Nov 30, 2024 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Oct 18, 2023

Study contacts

Haiyan Qian, MD, PhD
Contact
ahqhy712@163.com
+8613811386143
Zhiyao Wei
Contact
weizhiyaoyx@163.com
+8615521192379
Haiyan Qian, MD, PhD
principal investigator · Fuwai Hospital, Beijing, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion